Source - RNS
RNS Number : 2484F
Syncona Limited
11 July 2019
 

Syncona Limited

Issue of shares pursuant to Long Term Incentive Plan and PDMR dealings

11 July 2019

Syncona Limited (the "Company") today announces that a total of 1,583,138 new ordinary shares will be issued in satisfaction of realisations under the Company's Long Term Incentive Plan.  The new ordinary shares, when issued, will rank pari passu with the existing issued ordinary shares of the Company. In accordance with the rules of the Long Term Incentive Plan, the number of ordinary shares to be issued has been calculated using the closing mid-market price on 10 July 2019, £2.17.

In accordance with the rules of the Long Term Incentive Plan, ordinary shares delivered on realisation may not be sold or transferred by the recipient for a period of one year following the realisation date.

The issue of shares include the following shares to be issued to senior members of the Syncona Investment Management Limited (SIML) leadership team:

Name

SIML Title

No. of shares to be issued

Martin Murphy

Chief Executive Officer

508,879

Chris Hollowood

Chief Investment Officer

286,996

John Bradshaw

Chief Financial Officer

101,143

Application has been made to the Financial Conduct Authority for the shares to be admitted to the Official List, and to the London Stock Exchange for the shares to be admitted to trading and it is expected that dealings will commence in the new ordinary shares on 17 July 2019.

Notification of transactions by Persons Discharging Managerial Responsibilities ("PDMRs") are set out below.

[ENDS]

Enquiries

Syncona Ltd

Siobhan Weaver / Annabel Clay  

Tel : +44 (0) 20 3981 7940

 

FTI Consulting

Brett Pollard / Natalie Garland-Collins

Tel: +44 (0) 20 3727 1000

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com  

About Syncona

Syncona is a leading FTSE250 healthcare company focused on founding, building and funding global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.

We take a long-term view, underpinned by a deep pool of capital, and are established leaders in gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Martin Murphy

b)

Position / status

Chief Executive Officer, SIML

c)

Initial notification / amendment

Initial Notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares 

GG00B8P59C08

b)

Nature of the transaction

Issue of shares pursuant to the Syncona Long Term Incentive Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

2.17

508,879

d)

Aggregated information

Aggregated volume

Price

 

 

N/A

e)

Date of the transaction

11 July 2019

f)

Place of the transaction

Outside a trading venue

g)

Currency

GBP - British Pound

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Chris Hollowood

b)

Position / status

Chief Investment Officer, SIML

c)

Initial notification / amendment

Initial Notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares 

GG00B8P59C08

b)

Nature of the transaction

Issue of shares pursuant to the Syncona Long Term Incentive Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

2.17

286,996

d)

Aggregated information

Aggregated volume

Price

 

 

N/A                                                      

e)

Date of the transaction

11 July 2019

f)

Place of the transaction

Outside a trading venue

g)

Currency

GBP - British Pound

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

John Bradshaw

b)

Position / status

Chief Financial Officer, SIML

c)

Initial notification / amendment

Initial Notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares 

GG00B8P59C08

b)

Nature of the transaction

Issue of shares pursuant to the Syncona Long Term Incentive Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

2.17

101,143

d)

Aggregated information

Aggregated volume

Price

 

 

N/A

e)

Date of the transaction

11 July 2019

f)

Place of the transaction

Outside a trading venue

g)

Currency

GBP - British Pound

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
IOEBFLFFKDFFBBD